Dear EditorDengue fever (DF) is the most significant emerging arbovirus disease,which is caused by four distinct serotypes of Dengue viruses (DENV-1 to DENV-4).Serotype-specific immunity does not confer cross-protection against secondary infections from heterologous serotypes,which leads to dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS) as a result of antibody-dependent enhancement (ADE) of infection that is mediated by non-neutralizing,cross-reactive antibodies (Kliks et al.,1989).The intense efforts to develop a safe and efficient DENV vaccine have involved using a variety of traditional biological technologies in the past 50 years (Durbin et al.,2005;McArthur et al.,2008),yet no commercial DENV vaccine has been generated until now.